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To assess the economic impact of Lyme disease (LD),
the most common vectorborne inflammatory disease in the
United States, cost data were collected in 5 counties of the
Maryland Eastern Shore from 1997 to 2000. Patients were
divided into 5 diagnosis groups, clinically defined early-
stage LD, clinically defined late-stage LD, suspected LD,
tick bite, and other related complaints. From 1997 to 2000,
the mean per patient direct medical cost of early-stage LD
decreased from $1,609 to $464 (p<0.05), and the mean per
patient direct medical cost of late-stage LD decreased from
$4,240 to $1,380 (p<0.05). The expected median of all
costs (direct medical cost, indirect medical cost, nonmed-
ical cost, and productivity loss), aggregated across all diag-
nosis groups of patients, was ≈$281 per patient. These
findings will help assess the economics of current and
future prevention and control efforts.
L
yme disease (LD) is a multisystem, multistage, inflam-
matory tickborne disorder caused by the spirochete
Borrelia burgdorferi. LD usually begins with an initial
expanding skin lesion, erythema migrans (EM), which
may be followed by musculoskeletal, neurologic, and car-
diac manifestations in later stages of the disease (1–3).
Enzyme-linked immunosorbent assay and Western blotting
test are widely used to diagnose LD (4–6). LD is most
responsive to antimicrobial drugs in the early stage, while
further intensive therapy may be necessary in the late stage
(7,8). A variety of prevention and control procedures can
be implemented to prevent and reduce LD incidence,
including, but not limited to, public education; personal
protection measures such as wearing protective clothing
(gloves, long clothes), checking one’s body daily for ticks,
avoiding tick-infested areas, and applying tick repellent
(DEET, permethrin); host management; habitat modifica-
tion; and chemical control (9,10). In 1998, the Food and
Drug Administration approved a recombinant outer-sur-
face protein A(rOspA) LD vaccine (LYMErix, SmithKline
Beecham Biologicals, Rixensart,  Belgium) for persons
15–70 years of age (11). However, in 2002, SmithKline
withdrew the vaccine, citing low demand. Therefore, per-
sonal protection measures, early diagnosis, and early treat-
ment are extremely important in preventing and
controlling LD.
Since the first case reported in 1975 (12), LD has
become the most common vectorborne inflammatory dis-
ease in the United States. Foci of LD are widely spread in
the northeastern, mid-Atlantic, and north-central regions
of the United States (13). Despite federal, state, and local
efforts to prevent and control LD, total reported cases of
LD increased almost 3-fold from 1991 to 2002 (Figure 1).
In 2002, the Centers for Disease Control and Prevention
(CDC) received reports of 23,763 LD cases, 95% of which
were from Connecticut, Delaware, Maine, Maryland,
Massachusetts, Minnesota, New Hampshire, New Jersey,
New York, Pennsylvania, Rhode Island, and Wisconsin
(14). In Maryland, the overall incidence of LD was more
than twice as high as the overall incidence of LD in the
United States (13.0 vs. 6.3 cases per 100,000 population)
(13).
Assessing the economic impact of LD will help assess
the economics of current and future prevention and control
efforts. Although several studies of cost estimates of LD
have been published (e.g., 15), information on the econom-
ic impact of LD is limited. Therefore, we conducted a 4-
year study to estimate the economic impact of LD on the
Maryland Eastern Shore.
Methods
Study Population and Data
This study was conducted in 5 counties (Caroline,
Dorchester, Kent, Queen Anne, and Talbot) on the
Maryland Eastern Shore, an area where LD is endemic
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Hygiene, Baltimore, Maryland, USA(Table 1). The study population includes patients living in
the 4 counties enrolled in Delmarva Health Plan (DHP, a
managed healthcare organization) and non-DHP patients
receiving health care from office-based physicians in Kent
County from 1997 to 2000. Eligible patients were identi-
fied through records of encounters for LD, tick bites, insect
bites, and serologic testing for LD antibodies. During 1997
and 1998, identified patients were contacted for informed
consent. Patients who indicated that they did not wish to
participate were excluded from our database. A cost and
risk questionnaire (Appendix 1 available online at
www.cdc.gov/ncidod/EID/vol12no04/05-0602_app1.htm)
was sent to patients who gave informed consent. The
response rate of the survey was ≈22%. Interviewers then
reviewed patients’ charts and consulted relevant sources
(e.g., hospital, physician office, laboratory) to obtain the
following information: patient demographics; insurance
coverage; diagnosis; symptoms; dates of onset and diagno-
sis; dates of tick bite exposure; dates and costs of primary
provider and consultant visits; dates and costs of hospital-
izations and emergency department visits; dates, results,
and costs of laboratory tests; and dates and costs of antimi-
crobial drug treatment. All abstracted information was kept
confidential. After 1999, an anonymous abstraction of
medical records was approved by the institutional review
board (IRB) and implemented, allowing inclusion of more
patients for all 4 study years, with the exclusion of the
records of those who had previously declined participa-
tion. All protocols of this study were approved by IRBs
from CDC, the state of Maryland, and the University of
Maryland. Those patients identified as having received an
LD vaccination were not included in this study.
Case Definition
For the purpose of surveillance, a case of LD is defined
as physician-diagnosed EM >5 cm or at least 1 late
rheumatologic, neurologic, or cardiac manifestation with
laboratory evidence of B. burgdorferi infection (16). These
criteria were developed as an epidemiologic case defini-
tion intended for surveillance purposes only. Although
such a standard may aid comparison across clinical studies
and facilitate development of research, exposure history
and clinical features are critical. For example, treating
patients with seasonal (summer) musculoskeletal flulike
symptoms in areas where LD is endemic may be clinically
appropriate (12). Because the data for this study were col-
lected directly from healthcare organizations and physi-
cians, we used a clinical definition of LD. This definition
was based on physicians’ determination in the medical
record, according to patients’ clinical findings, tick expo-
sure, and other relevant details (e.g., laboratory results).
In our study, LD patients were identified by using a
final diagnosis code in their medical records. LD patients
were then divided into 5 diagnosis groups: clinically
defined early-stage LD, clinically defined late-stage LD,
suspected LD, tick bite, and other related complaints. Most
clinically defined early-stage LD patients had EM; some
also had musculoskeletal flulike symptoms such as
malaise, fatigue, headache, fever, and chills (12). In this
study, clinically defined late-stage LD patients included
those with later manifestations (neurologic involvement,
cardiac involvement, and arthritis) and patients with
chronic LD. The diagnosis groups of suspected LD, tick
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Figure 1. Lyme disease (LD) cases reported to the Centers for
Disease Control and Prevention by state health departments in the
United States (1991–2002). Reported cases were defined accord-
ing to the national surveillance definition. For the purpose of sur-
veillance, a case of LD is defined as physician-diagnosed
erythema migrans >5 cm or >1 late rheumatologic, neurologic, or
cardiac manifestation with laboratory evidence of Borrelia burgdor-
feri infection. Available from http://www.cdc.gov/ncidod/dvbid/
lyme/epi.htm (14). bite, and other related complaints involved all patients
without a clear final diagnosis of LD. Suspected LD
referred to patients who had some symptoms that could be
indicative of LD without further evidence and thus no
definitive diagnosis of LD. Patients with tick bites without
symptoms were placed in the tick bite group. The diagno-
sis group of other related complaints included all other
diagnoses that were different from the above 4 diagnosis
groups, such as unknown insect bites and screening among
asymptomatic persons.
Study Design
We calculated the following total costs of LD: 1) direct
medical costs of LD diagnosis and treatment, 2) indirect
medical costs, 3) nonmedical costs, and 4) productivity
losses. Intangible costs (e.g., costs incurred because of
pain and suffering) were not incorporated. Consumer price
index (CPI) for medical care was used to adjust all medical
payments into year 2000 dollars (17). For nonmedical
costs and productivity losses, we adjusted costs by using
the general CPI. We took a societal perspective, which
incorporates all costs and all benefits no matter who pays
costs or who receives benefits.
Charges were used to estimate the direct medical cost.
To determine the direct medical costs associated with LD,
we used charge data from both DHP and office-based
healthcare providers in Kent County. Direct medical costs
of LD included costs (charges) of physician visits, consul-
tation, serology, procedure, therapy, hospitalization/emer-
gency room (ER), and other related costs (Appendix 2
available online at www.cdc.gov/ncidod/EID/vol12no04/
05-0602_app2.htm). 
Indirect medical costs, nonmedical costs, and produc-
tivity losses were all acquired from a patient questionnaire
used in 1997 and 1998. The questionnaire was sent to LD
patients with informed consent forms. Collection of these
data was restricted to those 2 years. In this study, indirect
medical costs refer to extra prescription and nonprescrip-
tion drug costs that patients paid out of pocket.
The patient’s questionnaire also collected information
on nonmedical payments made for home or health aides
and miscellaneous services, such as travel (transportation)
and babysitting. Each patient’s transportation costs to a
physician’s office were estimated by using the US federal
government reimbursement rate, multiplying the reported
total travel miles per patient by $0.365/mile. Total travel
mileage per patient was calculated by counting the number
of physician visits and multiplying total visits by the dis-
tance of a round trip to the physician’s office.
We used patient-reported time lost from work to esti-
mate productivity losses due to LD on the basis of the
human capital method and valued the time lost by using
age-  and sex-weighted productivity valuation tables (18).
Because of the potential complexity of accurately answer-
ing the question, we did not ask patients to estimate the
time they lost from household production. We did, howev-
er, ask patients if they paid anybody to do household tasks
because their LD-related infirmities prevented them from
doing those tasks. For patients <15 years of age, we
assumed that their parents (usually the mother) had to take
time off from their work to take care of them. Therefore,
their mothers’ values of lost days of work were included.
Analysis
We used the following formula to estimate the average
per capita cost of LD, i.e., the mean cost (direct medical
costs, indirect medical costs, nonmedical costs, and pro-
ductivity losses) aggregated across all diagnosis groups of
patients:
Expected mean cost of a LD outcome = Σ direct medical costs,
indirect medical costs, nonmedical costs, and productivity losses (Mean cost of
outcome clinically defined early-stage LD, clinically defined late-stage LD, suspect-
ed LD, tick bite, and other related complaints × Probability of outcome clin-
ically defined early-stage LD, clinically defined late-stage LD, suspected LD, tick bite,
and other related complaints).
Because the distribution of cost data is often not nor-
mal, we also calculated the medians of these costs and
used both mean and median to estimate the most likely per
capita cost of LD on the Maryland Eastern Shore. The
median cost of an LD outcome was calculated by using the
following formula:
Expected median cost of a LD outcome = Σ direct medical
costs, indirect medical costs, nonmedical costs, and productivity losses (Median
cost of outcome clinically defined early-stage LD, clinically defined late-stage
LD, suspected LD, tick bite, and other related complaints ×Probability of out-
come clinically defined early-stage LD, clinically defined late-stage LD, suspected LD,
tick bite, and other related complaints)
Differences between annual mean direct medical costs
were analyzed by using 1-way analysis of variance fol-
lowed by a Bonferroni test. Differences were considered
significant for p values <0.05. Additionally, we used a mul-
tivariate linear regression model to estimate the relative
impact of a number of factors on the direct medical costs of
LD. The ordinary linear regression (OLS) method was
applied by using SAS 8.2 (SAS Institute, Cary, NC, USA)
and Stata SE (StataCorp LP, College Station, TX, USA).
The dependent variable was total direct medical cost per
LD patient. We transformed total direct medical costs by
using natural logarithms because the data were highly
skewed. Independent variables of the equation included
cohort year, LD diagnosis groups, diagnostic and treatment
procedures, and patient characteristics (e.g., sex, age). All
independent variables, except age, were binomial (yes = 1,
no = 0). Baseline costs (i.e., the intercept term in the regres-
sion equation) referred to those costs accrued by a woman
who had tick bite only (without EM symptoms) diagnosed
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tal or ER stay, no serologic tests, no consultation from other
physicians, no antimicrobial drug therapy, and no other pro-
cedures outside a physician office and hospital/ER.
Additional direct medical costs were added or subtracted to
the baseline costs for each independent variable of interest
if significant (Appendix 3, available online at
http://www.cdc.gov/      ncidod/EID/vol12no04/05-
0602_app3.htm). We tested heteroscedasticity in Stata and
corrected mild heteroscedasticity by using “robust” and
“hc3” procedures. We also tested both linearity and multi-
collinearity in SAS and Stata. 
Results
From 1997 to 2000, we identified 3,415 LD-relevant
patients in the 5 counties studied on Maryland Eastern
Shore (Table 2). Among them, 10% had clinically defined
early-stage LD while almost 5% of all patients had clini-
cally defined late-stage LD. Of 284 patients who returned
a completed patient questionnaire, 59 patients had clinical-
ly defined early-stage LD; 25 patients had clinically
defined late-stage LD.
Table 3 provides cohort years, medians, means, and
standard deviations of direct medical costs comparing the
different diagnosis groups. During the study’s time frame,
the mean (range) direct medical cost of clinically defined
early-stage LD decreased from $1,609 ($95–$11,286) in
1997 to $464 ($5–$5,338) in 2000 (p<0.05). The mean
direct medical cost of clinically defined late-stage LD
decreased from $4,240 ($275–$24,985) in 1997 to $1,380
($45–$6,918) in 2000 (p<0.05).
From 1997 to 2000, the mean cost of therapy of all
diagnosis groups decreased 75%, from $189 to $47, and
the mean cost of hospitalization/ER decreased 61%, from
$41 to $16 (Figure 2). During the same period, the mean
cost of an office visit, consultation, and serologic tests also
decreased 20%, 15%, and 4%, respectively. Additionally,
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(95th percentile for all 4 years) of therapy cost gradually
decreased from 8% in 1997 to 7% in 1998, to 4% in 1999,
and 3% in 2000 (data available upon request). 
Apatient with clinically defined early-stage LD paid an
average of $164 in 1997 and $307 in 1998 (in 2000 dol-
lars) for extra prescription and nonprescription drugs
(Table 4). Those with clinically defined late-stage LD paid,
for similar items, an average of $579 in 1997 and $389 in
1998. The mean nonmedical cost for clinically defined
early-stage LD was $109 in 1997 and $23 in 1998. For
patients with clinically defined late-stage LD, mean non-
medical costs were $60 in 1997 and $6,703 in 1998.
During the survey period, the mean productivity loss of
clinically defined early-stage LD was $411 in 1997 and
$88 in 1998, and the mean productivity loss of clinically
defined late-stage LD was $7,762 in 1997 and $9,108 in
1998. For all 3 types of costs shown in Table 4, a large dif-
ference was seen between mean and median values, with
the latter often less than half of the mean value, indicating
that a small number of LD patients account for a large por-
tion of total costs.
Using multivariate linear regression analysis, we found
that patients with clinically defined early- and late-stage
LD had direct medical costs that were ≈50% and 100%,
respectively, higher (p<0.001) relative to patients who
only had tick bite, if the impact from other factors was not
considered (Table 5). Moreover, patients who were hospi-
talized or made ER visits, who underwent serologic test-
ing, who needed therapy, who were referred for
consultation, and who had other procedures had substan-
tially (p<0.001) higher direct medical cost than those who
did not (Table 5). No cost difference was seen between
men and women. After controlling for other factors, direct
medical costs per LD patient in 2000 were lower than
those in 1997 (Table 5).
In year 2000 dollars, the expected mean total cost
attributable to LD was $1,965 per patient, and the expect-
ed median total cost attributable to LD was estimated at
$281 per patient (Figure 3). For LD patients at the clinical-
ly defined early stage, the median total cost was ≈$397
(mean $1,310), whereas for patients at the clinically
defined late stage, the median cost rose to $923 (mean
$16,199). Suspected LD cases, tick bite cases, and other
LD-related complaints had median costs of $238 (mean
$461), $108 (mean $316), and $256 (mean $714), respec-
tively.
Economic Impact of Lyme Disease
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 4, April 2006 657
Figure 2. Distribution of elements of direct medical cost (US$) per
Lyme disease (LD) patient in Maryland Eastern Shore
(1997–2000). Mean is based on direct medical costs of LD
patients. Direct medical costs were collected from medical record
abstraction (1997–2000). Direct medical costs of LD included
costs of physician visits, consultation, serologic tests, procedure,
therapy, hospitalization/emergency room, and other relevant
costs. All costs were converted to 2000 equivalent. Discussion
Previous studies of the economic impact of LD were
often based on numerous assumptions and experts’ sug-
gestions (e.g., Maes et al. [15]). Only a few studies provid-
ed cost estimates of LD based on data collected from the
field (e.g., Fix et al. [19], Strickland et al. [20]). Even in
those studies, however, cost estimates only related to
direct medical charges or certain diagnosis or treatment
procedures. By combining data from medical records with
results from a patient survey, this study more comprehen-
sively documents the economic impact of LD from a soci-
etal perspective. 
To approximate the annual economic impact of LD
nationwide, we extrapolated our results to the total number
of LD cases reported nationwide. In this study, the annual
total direct medical cost of LD cases on Maryland Eastern
Shore was $1,455,081; 490 cases were in the clinically
defined early or late stage of LD. Total indirect medical
costs, nonmedical costs, and productivity losses were
$436,949; 84 cases were clinically defined early- or late-
stage LD. Therefore, in general, an LD patient (clinically
defined early or late stage) costs $2,970 in direct medical
costs plus $5,202 in indirect medical costs, nonmedical
costs, and productivity losses. In 2002, 23,763 LD cases
were reported to CDC. Hence, the estimated nationwide
annual economic impact of LD and relevant complaints
was ≈$203 million (in 2002 dollars). However, since LD
cases reported on the basis of the surveillance case defini-
tion are believed to be underreported (13,21), this nation-
wide estimate is likely to be low.
We found that the average cost per LD case decreased
over the study period. In LD-endemic areas, personal pro-
tection measures are frequently emphasized and insecti-
cides are widely used (22). Persons in LD-endemic areas
likely visit physicians more frequently whenever they have
an exposure or an insect bite, and physicians attending
patients from an LD-endemic area likely order serologic
testing for possible LD patients and provide prompt treat-
ment. However, our current evidence was limited in that
we were only able to find a decrease in per capita cost
within diagnosis groups (e.g., clinically defined early- and
late-stage LD), but we could not find a shift in the number
of cases from late to early stage. Therefore, we don’t know
what caused the decrease in average cost per LD case.
This study has certain limitations. First, we used clini-
cal case definition (physician determination) instead of
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Thus, we may have overestimated the number of LD cases.
As a result of case definition, our estimation of cost not
only included the cost of LD (clinically defined early- and
late-stage LD) but also the costs of LD-relevant complaints
(suspected LD, tick bite, and other related complaints).
Second, medical charges used in our study may not reflect
the true cost. Third, our results are likely to underestimate
the costs per case because some of the costs were not
included. Costs that were omitted included any costs
incurred by a patient beyond the study period. Likewise,
Steer et al. reported that ≈7% of LD cases remained
asymptomatic within the 20-month study (23). These
asymptomatic patients may have costs beyond the study.
Public health surveillance and administration costs and
intangible costs (e.g., costs incurred because of pain and
suffering) were also not incorporated in the study. Fourth,
because of the large variance between mean and median
costs, using mean cost to estimate national impact could be
an overestimation. Finally, this study is also limited in that
we only had information for indirect medical costs, non-
medical costs, and productivity losses from ≈8% of total
patients in the study. Therefore, the results from survey
data were extrapolated to represent the whole study popu-
lation. This method may have biased our results. 
LD is the most common vectorborne zoonotic inflam-
matory disease in the United States. The longterm seque-
lae of LD are debilitating to patients and costly to society.
The emergence of LD and previous experience predict the
feasibility of public health interventions for LD control
and prevention (24). More research on the social behavior
of LD patients and economic evaluation of LD prevention
interventions is needed.
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